Medical devices, healthcare technology and the business of care
510(k) clearance · K260396

KCS rTMS Therapy System (Transcranial Magnetic Stimulator) (MetaStim 100, MetaStim 100A)

Fidelity BioPharma Co. · Decision date Sep 6, 2026

MEDTECHLEDGER EXPLANATIONK260396

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 6, 2026 for K260396, a traditional 510(k) from Fidelity BioPharma Co. of New Haven, Connecticut, for the KCS rTMS Therapy System (Transcranial Magnetic Stimulator), models MetaStim 100 and MetaStim 100A. The device is a Class II repetitive transcranial magnetic stimulation system under 21 CFR 882.5805, product code OBP, in the Neurology panel. Clearance is not PMA approval.

The submission describes a host with master control unit, power supply, software and cooling unit, plus an MD-60 figure-of-eight stimulation coil; motor evoked potential, coil stand and MetaStim software are optional. The sponsor states the primary predicate is Ultimate rTMS/Yingchi rTMS (K230735), with Neurosoft TMS/CloudTMS (K173441) as a reference device, and reports the same intended use, product code and regulation. The summary states differences raise no new safety or effectiveness questions. Coil dimensions differ, marked "Similar Note 1," but the note's content is not in the provided excerpts.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Sep 6, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260396
Regulatory pathway
510(k) premarket notification
Product code
OBP
Decision code
SESE
Decision date
Sep 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transcranial Magnetic Stimulator.

Product code
OBP
FDA device class
2

FDA decision timeline

  1. K260396 received

    Application receipt date recorded by FDA.

  2. K260396 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Fidelity BioPharma Co.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
New Haven, CT

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records